T2 Biosystems Inc (NASDAQ:TTOO) fell 12.7% during mid-day trading on Thursday . The company traded as low as $3.44 and last traded at $3.45. 619,441 shares changed hands during mid-day trading, an increase of 134% from the average session volume of 264,171 shares. The stock had previously closed at $3.95.
A number of research firms have issued reports on TTOO. Zacks Investment Research upgraded shares of T2 Biosystems from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Thursday, November 8th. ValuEngine downgraded shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Cantor Fitzgerald set a $11.00 target price on shares of T2 Biosystems and gave the stock a “buy” rating in a research report on Friday, November 2nd. HC Wainwright set a $14.00 target price on shares of T2 Biosystems and gave the stock a “buy” rating in a research report on Friday, November 2nd. Finally, Goldman Sachs Group set a $5.00 target price on shares of T2 Biosystems and gave the stock a “hold” rating in a research report on Friday, November 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $8.94.
The company has a debt-to-equity ratio of 1.66, a current ratio of 7.16 and a quick ratio of 6.81.
Institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new position in shares of T2 Biosystems during the 3rd quarter valued at $242,000. Creative Planning acquired a new position in T2 Biosystems in the 3rd quarter valued at $112,000. Virtu Financial LLC acquired a new position in T2 Biosystems in the 4th quarter valued at $107,000. Northern Trust Corp grew its stake in T2 Biosystems by 474.7% in the 2nd quarter. Northern Trust Corp now owns 312,079 shares of the medical equipment provider’s stock valued at $2,416,000 after buying an additional 257,772 shares during the last quarter. Finally, Bell Rock Capital LLC grew its stake in T2 Biosystems by 10.4% in the 4th quarter. Bell Rock Capital LLC now owns 322,135 shares of the medical equipment provider’s stock valued at $971,000 after buying an additional 30,300 shares during the last quarter. Institutional investors and hedge funds own 54.65% of the company’s stock.
TRADEMARK VIOLATION WARNING: “T2 Biosystems (TTOO) Stock Price Down 12.7%” was first posted by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4134391/t2-biosystems-ttoo-stock-price-down-12-7.html.
T2 Biosystems Company Profile (NASDAQ:TTOO)
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Read More: Correction
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.